Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Bluebird bio | Rare Historical Photos

US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Intraday Session

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2022

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million.

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Looking Into bluebird bio's Return On Capital Employed

Looking Into bluebird bio's Return On Capital Employed

According to Benzinga Pro data, during Q1, bluebird bio (NASDAQ:BLUE) posted sales of $1.95 million. Earnings were up 21.22%, but bluebird bio still reported an overall loss of $122.15 million.

Analyst Ratings for bluebird bio

Analyst Ratings for bluebird bio

Over the past 3 months, 6 analysts have published their opinion on bluebird bio (NASDAQ:BLUE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Expert Ratings For bluebird bio

Expert Ratings For bluebird bio

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Why Bluebird Bio Shares Are Tumbling Today

Why Bluebird Bio Shares Are Tumbling Today

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

1

Organisations

Food and Drug Administration

BristolMyers Squibb

Vertex Pharmaceuticals

HC Wainwright & Co

Builders FirstSource

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Prescription Drug

Sickle Cell Disease

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

382,492 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play